The role of sclerostin in lipid and glucose metabolism disorders
Biochemical Pharmacology · 2023-09 · 215 · 115694
DOI: 10.1016/j.bcp.2023.115694 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Biochemical Pharmacology, 2023-09. Verfasst von Hewen Jiang und 15 weiteren Autor:innen. Beteiligte Einrichtung: School of Chinese Medicine, Chinese University of Hong Kong, Hong Kong, China; Guangdong-Hong Kong Macao Greater Bay Area International Research Plat…. Hauptthemen laut MEDLINE: Proteins, Glucose Metabolism Disorders. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 218 Literaturangaben. Gefördert von: Research Grants Council, University Grants Committee, Chinese University of Hong Kong, Guangdong Provincial Department of Science and Technology.
Abstract (Originalsprache)
Lipid and glucose metabolism are critical for human activities, and their disorders can cause diabetes and obesity, two prevalent metabolic diseases. Studies suggest that the bone involved in lipid and glucose metabolism is emerging as an endocrine organ that regulates systemic metabolism through bone-derived molecules. Sclerostin, a protein mainly produced by osteocytes, has been therapeutically targeted by antibodies for treating osteoporosis owing to its ability to inhibit bone formation. Moreover, recent evidence indicates that sclerostin plays a role in lipid and glucose metabolism disorders. Although the effects of sclerostin on bone have been extensively examined and reviewed, its effects on systemic metabolism have not yet been well summarized. In this paper, we provide a systemic review of the effects of sclerostin on lipid and glucose metabolism based on in vitro and in vivo evidence, summarize the research progress on sclerostin, and prospect its potential manipulation for obesity and diabetes treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chinese Medicine, Chinese University of Hong Kong, Hong Kong, China; Guangdong-Hong Kong Macao Greater Bay Area International Research Platform for Aptamer-Based Translational Medicine and Drug Discovery, Hong…
- Guangdong-Hong Kong Macao Greater Bay Area International Research Platform for Aptamer-Based Translational Medicine and Drug Discovery, Hong Kong, China; Law Sau Fai Institute for Advancing Translational Medicine in Bon…
Förderung
- Research Grants Council, University Grants Committee
- Chinese University of Hong Kong
- Guangdong Provincial Department of Science and Technology
- National Key Research and Development Program of China
- Hong Kong Baptist University
Zitieren
APA
Jiang, H., Li, D., Han, Y., Li, N., Tao, X., Liu, J., Zhang, Z., Yu, Y., Wang, L., Yu, S., Zhang, N., Xiao, H., Yang, X., Zhang, Y., Zhang, G., & Zhang, B. T. (2023). The role of sclerostin in lipid and glucose metabolism disorders. Biochemical Pharmacology, 215, 115694. https://doi.org/10.1016/j.bcp.2023.115694
Vancouver
Jiang H, Li D, Han Y, Li N, Tao X, Liu J, et al. The role of sclerostin in lipid and glucose metabolism disorders. Biochemical Pharmacology. 2023;215:115694. doi:10.1016/j.bcp.2023.115694
BibTeX
@article{Jiang2023,
author = {Jiang, Hewen and Li, Dijie and Han, Ying and Li, Nanxi and Tao, Xiaohui and Liu, Jin and Zhang, Zongkang and Yu, Yuanyuan and Wang, Luyao and Yu, Sifan and Zhang, Ning and Xiao, Huan and Yang, Xin and Zhang, Yihao and Zhang, Ge and Zhang, Bao-Ting},
title = {The role of sclerostin in lipid and glucose metabolism disorders},
journal = {Biochemical Pharmacology},
year = {2023},
volume = {215},
pages = {115694},
doi = {10.1016/j.bcp.2023.115694}
}
EUVIMED